Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vanderbilt-Ingram Cancer Center
With
United States Department of Defense
Primary Objective:
\- Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy
Exploratory Objective:
\- Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Renal Cell Carcinoma with clear cell component
Stage IV
Receiving IO-containing regimen
Measurable disease per RECIST 1.1
Clareo Health | Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
